Clinical Research of Genetically Modified Dendritic Cells in Combination with Cytokine-induced Killer Cell Treatment in Advanced Renal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2014 Apr 12

PMID 24720900

Citations 31

Authors

Danhong Wang

Bin Zhang

Haiyan Gao

Guoliang Ding

Qiong Wu

Jinchao Zhang

Li Liao

Hu Chen

Affiliations

Soon will be listed here.

Abstract

Background: Renal cell carcinoma (RCC) is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. Yet Active immunization using genetically modified dendritic cells holds promise for the adjuvant treatment of malignancies to eradicate or control residual disease. Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD8+ T cells with diverse TCR specificities, possessing non-MHC-restricted cytolytic activities against tumor cells. Clinical studies have confirmed benefit and safety of CIK cell-based therapy for patients with malignancies. This clinical trial was conducted to evaluate efficacy and safety of genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell (gmDCs-CIK) treatment of patients with RCC.

Methods: 28 patients with advanced renal cancer were admitted to Affiliated Hospital of Academy of Military Medical Sciences from December 2010 to March 2012 and treated by gmDCs-CIK. Clinical efficacy and safety between pre- and post-treatment were compared.

Results: This analysis showed an objective response rate (ORR) of 39% and a disease control rate (DCR) of as 75%. There is no significant relationship between clinical efficacy and whether metastasis occurred or not (P > 0.05). There is no significant relationship between ORR and cycles of treatment (P > 0.05), but DCR was significantly related with cycles of treatment (P < 0.05). No clinically significant side effects were observed. There were no significant changes of T cell subsets including CD3+, CD4+, CD8+, CD4+ CD25+ Treg cells except Th1 in peripheral blood between day 30 after immunotherapy and 1 day before immunotherapy in 11 patients.

Conclusion: DC-CIK is feasible and effective in treating advanced renal cancer and thus provides a new approach.

Trial Registration: ClinicalTrials.gov Identifier: NCT01924156. Registration date: August 14, 2013.

Citing Articles

Immune-Based and Novel Therapies in Variant Histology Renal Cell Carcinomas.

Miller J, Johnson J, Guske C, Mannam G, Hatoum F, Nassar M Cancers (Basel). 2025; 17(2).

PMID: 39858107 PMC: 11763753. DOI: 10.3390/cancers17020326.

Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.

Chen J, Duan Y, Che J, Zhu J Cancer Commun (Lond). 2024; 44(9):1047-1070.

PMID: 39051512 PMC: 11492303. DOI: 10.1002/cac2.12596.

The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.

Han J, Zhang B, Zheng S, Jiang Y, Zhang X, Mao K Cell Transplant. 2024; 33:9636897241231892.

PMID: 38433349 PMC: 10913519. DOI: 10.1177/09636897241231892.

mRNA cancer vaccines: Advances, trends and challenges.

He Q, Gao H, Tan D, Zhang H, Wang J Acta Pharm Sin B. 2022; 12(7):2969-2989.

PMID: 35345451 PMC: 8942458. DOI: 10.1016/j.apsb.2022.03.011.

Combination of oncolytic adenovirus ZD55 harboring TRAIL-IETD-MnSOD and cytokine-induced killer cells against lung cancer.

Jiang R, Zhang Z, Liao X, Huang L, Liao Y, Deng W Ann Transl Med. 2021; 9(20):1527.

PMID: 34790733 PMC: 8576688. DOI: 10.21037/atm-21-4479.

References

Figdor C, de Vries I, Lesterhuis W, Melief C . Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10(5):475-80. DOI: 10.1038/nm1039. View

Yang B, Lu X, Zhu H, Han W, Wang Y, Fan H . [Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18(5):1244-9. View

Knutson K, Disis M . Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005; 54(8):721-8. PMC: 11032889. DOI: 10.1007/s00262-004-0653-2. View

Motzer R, Mazumdar M, Bacik J, Russo P, Berg W, Metz E . Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol. 2000; 18(9):1928-35. DOI: 10.1200/JCO.2000.18.9.1928. View

Schmidt-Wolf I, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N . Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999; 81(6):1009-16. PMC: 2362953. DOI: 10.1038/sj.bjc.6690800. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Maroto J, Del Muro X, Mellado B, Perez-Gracia J, Andres R, Cruz J . Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC). Clin Transl Oncol. 2013; 15(9):698-704. DOI: 10.1007/s12094-012-0991-z. View

Hirschowitz E, Foody T, Hidalgo G, Yannelli J . Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer. 2007; 57(3):365-72. PMC: 2063443. DOI: 10.1016/j.lungcan.2007.04.002. View

Atzpodien J, Kirchner H, Jonas U, Bergmann L, Schott H, Heynemann H . Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol. 2004; 22(7):1188-94. DOI: 10.1200/JCO.2004.06.155. View

10.

Yagoda A, Bander N . Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int. 1989; 44(6):338-45. DOI: 10.1159/000281537. View

11.

Hoos A, Eggermont A, Janetzki S, Hodi F, Ibrahim R, Anderson A . Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010; 102(18):1388-97. PMC: 2943524. DOI: 10.1093/jnci/djq310. View

12.

Kraemer M, Hauser S, Schmidt-Wolf I . Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res. 2010; 30(6):2081-6. View

13.

Turnbull J, Cobert J, Jaffe T, Harrison M, George D, Armstrong A . Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2012; 11(1):45-50. DOI: 10.1016/j.clgc.2012.06.001. View

14.

Palucka K, Banchereau J, Mellman I . Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33(4):464-78. PMC: 2975953. DOI: 10.1016/j.immuni.2010.10.007. View

15.

Lesterhuis W, Haanen J, Punt C . Cancer immunotherapy--revisited. Nat Rev Drug Discov. 2011; 10(8):591-600. DOI: 10.1038/nrd3500. View

16.

Escudier B . Emerging immunotherapies for renal cell carcinoma. Ann Oncol. 2012; 23 Suppl 8:viii35-40. DOI: 10.1093/annonc/mds261. View

17.

Negrier S, Escudier B, Lasset C, Douillard J, Savary J, Chevreau C . Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med. 1998; 338(18):1272-8. DOI: 10.1056/NEJM199804303381805. View

18.

Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf I . Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?. Leuk Res. 2011; 35(9):1136-42. DOI: 10.1016/j.leukres.2011.05.005. View

19.

Weber J . Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009; 58(5):823-30. PMC: 11030858. DOI: 10.1007/s00262-008-0653-8. View

20.

Sun Y, Chen J, Cai P, Hu Y, Zhong G, Feng H . [Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010; 18(1):219-23. View